Troldborg Anne, Bartels Lars Erik, Deleuran Bent
Ugeskr Laeger. 2020 May 11;182(20).
The severity of COVID-19 disease has led to an urgent need for the discovery of new treatments. Thus, global stocks of hydroxychloroquine (HCQ) have been put under pressure with a study of 26 patients treated with HCQ during their infection with SARS-CoV-2. Despite the study's lack of quality, several countries' medicines agencies subsequently issued guidelines for the use of HCQ for COVID-19. This review aims to elucidate potential mechanisms, which make HCQ treatment interesting in the fight against SARS-CoV-2 infection, as well as the current evidence for clinical use of HCQ to treat COVID-19.
新冠肺炎病情的严重性引发了对新治疗方法的迫切需求。因此，随着一项对26名感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）期间接受羟氯喹（HCQ）治疗的患者的研究，全球羟氯喹库存面临压力。尽管该研究质量欠佳，但几个国家的药品机构随后发布了使用羟氯喹治疗新冠肺炎的指南。本综述旨在阐明使羟氯喹治疗在抗击SARS-CoV-2感染中具有吸引力的潜在机制，以及目前羟氯喹用于治疗新冠肺炎的临床证据。
